Article
Immunology
Nathan Lawlor, Djamel Nehar-Belaid, Jessica D. S. Grassmann, Marlon Stoeckius, Peter Smibert, Michael L. Stitzel, Virginia Pascual, Jacques Banchereau, Adam Williams, Duygu Ucar
Summary: This study introduced a cost-effective high-throughput multiplexed single-cell RNA-seq method to examine the immune cell responses to classic T cell and monocyte activators. The results demonstrated that anti-CD3/CD28 treatment activated various lymphocyte classes, while LPS specifically targeted monocytes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Nina Worel, Katharina Grabmeier-Pfistershammer, Bernhard Kratzer, Martina Schlager, Andreas Tanzmann, Arno Rottal, Ulrike Koermoeczi, Edit Porpaczy, Philipp B. Staber, Cathrin Skrabs, Harald Herkner, Venugopal Gudipati, Johannes B. Huppa, Benjamin Salzer, Manfred Lehner, Nora Saxenhuber, Eleonora Friedberg, Philipp Wohlfarth, Georg Hopfinger, Werner Rabitsch, Ingrid Simonitsch-Klupp, Ulrich Jaeger, Winfried F. Pickl
Summary: Studies have found that low levels of CD3(+)CD27(-)CD28(-) T cells in lymphoma patients are associated with a favorable response to CART cell therapy, both in terms of overall response and complete remission. This finding highlights the importance of this pre-infusion blood biomarker in predicting the outcome of CAR-T cell treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Megan M. Wyatt, Logan W. Huff, Michelle H. Nelson, Lillian R. Neal, Andrew R. Medvec, Guillermo O. Rangel Rivera, Aubrey S. Smith, Amalia M. Rivera Reyes, Hannah M. Knochelmann, James L. Riley, Gregory B. Lesinski, Chrystal M. Paulos
Summary: IL-17-producing antigen-specific human T cells show strong antitumor activity in mice, but refinement is needed for clinical use. The influence of TCR and costimulation signal strength on Th17 immunity is unclear. We found that reducing TCR/costimulation signal strength altered Th17 phenotype and stimulated cells produced more cytokines. Lower signal strength Th17 cells were less reliant on glucose and more effective at clearing human mesothelioma.
Article
Biotechnology & Applied Microbiology
Yu-Yang Ng, Johan C. K. Tay, Zhendong Li, Junjian Wang, Jiangqing Zhu, Shu Wang
Summary: The study shows that T cells expressing NKG2D-DAP12 CAR have lower cytokine release during tumor cell lysis compared to those expressing the commonly used CD3 zeta activation domain, although there is no difference in mediating in vitro tumor cell lysis between the two CARs. Additionally, both types of CAR-T cells exhibit similar anti-tumor activity in tumor-bearing NSG mice, but NKG2D-CDg CAR-T cells lead to higher cytokine release and mortality due to xenogeneic graft versus host disease compared to NKG2D-DAP12 CAR-T cells. Incorporating the DAP12 activation domain in CAR design may provide a potential clinical advantage in mitigating the risk of cytokine release syndrome.
Article
Oncology
Rui Zhang, Qingxi Liu, Sa Zhou, Hongpeng He, Mingfeng Zhao, Wenjian Ma
Summary: In this study, a genetically modified bifunctional CAR-NK cell therapy was developed for the treatment of acute myeloid leukemia (AML). The bifunctional CD33/B16 CAR-NK cells showed superior killing efficiency towards AML cells compared to CAR-NK cells targeting CD33 only. In vivo studies also demonstrated effective clearance of leukemic cells and improved survival. These findings suggest a promising CAR-NK approach for AML treatment and potentially other tumors.
Article
Chemistry, Physical
Yurii P. Sharkeev, Ekaterina G. Komarova, Valentina V. Chebodaeva, Mariya B. Sedelnikova, Aleksandr M. Zakharenko, Kirill S. Golokhvast, Larisa S. Litvinova, Olga G. Khaziakhmatova, Vladimir V. Malashchenko, Kristina A. Yurova, Natalia D. Gazatova, Ivan G. Kozlov, Marina Y. Khlusova, Konstantin V. Zaitsev, Igor A. Khlusov
Summary: A modern trend in the medical fields of traumatology, orthopedics, and implantology involves the development of materials and coatings with an amorphous-crystalline structure for better biocompatibility. The study focused on the effects of different voltages during the deposition of calcium phosphate coatings on titanium plates using the micro-arc oxidation method. It was found that adjusting the voltage could significantly impact the physical and chemical properties of the coatings, influencing cellular behavior.
Article
Multidisciplinary Sciences
Nikos E. Papaioannou, Natallia Salei, Stephan Rambichler, Kaushikk Ravi, Jelena Popovic, Vanessa Kuentzel, Christian H. K. Lehmann, Remi Fiancette, Johanna Salvermoser, Dominika W. Gajdasik, Ramona Mettler, Denise Messerer, Joana Carrelha, Caspar Ohnmacht, Dirk Haller, Ralf Stumm, Tobias Straub, Sten Eirik W. Jacobsen, Christian Schulz, David R. Withers, Gunnar Schotta, Diana Dudziak, Barbara U. Schraml
Summary: The research demonstrates that early-life cDC2 have a dual hematopoietic origin, and although they exhibit different cytokine secretion and T cell polarizing abilities compared to adult cDC2, they are still functionally competent. Therefore, harnessing cDC2 in early life could be a potential strategy for boosting immunity.
NATURE COMMUNICATIONS
(2021)
Article
Biochemical Research Methods
Thidarat Kongkaew, Rattapoom Thaiwong, Suparat Tudsamran, Thitiya Sae-jung, Panjana Sengprasert, Apichai Vasuratna, Koramit Suppipat, Rangsima Reantragoon
Summary: This study compared the quality of T cell clones in ovarian cancer TILs using two different expansion methods. The results show that different stimulation methods lead to differences in TIL expansion and TCR repertoire patterns. The standard stimulation method resulted in similar TRBV chains in TIL-expanded clones, but there were also dominant T cell clones in only one subpopulation.
JOURNAL OF IMMUNOLOGICAL METHODS
(2022)
Article
Hematology
Marika Guercio, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Iolanda Boffa, Simona Caruso, Zeinab Abbaszadeh, Antonio Camera, Biancamaria Cembrola, Katia Bovetti, Simona Manni, Ignazio Caruana, Roselia Ciccone, Francesca Del Bufalo, Pietro Merli, Luciana Vinti, Katia Girardi, Annalisa Ruggeri, Cristiano De Stefanis, Marco Pezzullo, Ezio Giorda, Marco Scarsella, Rita De Vito, Sabina Barresi, Andrea Ciolfi, Marco Tartaglia, Lorenzo Moretta, Franco Locatelli, Concetta Quintarelli, Biagio De Angelis
Summary: A novel CAR.CD30 T cell therapy approach was designed and preclinically validated for chemotherapy-refractory or multiply relapsed CD30(+) NHL or HL. Through enhancing the co-stimulatory molecule CD28.OX40 in CAR.CD30 T cells, improved persistence and proliferation upon tumor encounter in vivo were achieved, leading to promising anti-tumor efficacy in HL and NHL xenograft mouse models.